Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.03, delivering a surprise of 57.14%.Over the last four quarters, the company has surpasse ...

P10, Inc. (PX) came out with quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.76%. A quarter ago, it was expected that this company would post earnings of $0.26 per share when it actually produced earnings of $0.30, delivering a surprise of 15.38%.Over the last four quarters, the company has surp ...

InfuSystems Holdings, Inc. (INFU) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.04, delivering a surprise of -50%.Over the last four quarters, the company ...

Enovis (ENOV) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.46%. A quarter ago, it was expected that this manufacturing and engineering company would post earnings of $0.92 per share when it actually produced earnings of $0.98, delivering a surprise of 6.52%.Over the last four qua ...

Core Viewpoint - Cenovus Energy reported quarterly earnings of $0.32 per share, exceeding the Zacks Consensus Estimate of $0.29 per share, but down from $0.46 per share a year ago, indicating a mixed performance in earnings despite a positive surprise this quarter [1][2]. Financial Performance - The company posted revenues of $9.26 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.18% and down from $9.94 billion year-over-year [2]. - Over the last four quarters, Cenovus has surpassed consensus EPS estimates only once, while topping revenue estimates two times [2]. Stock Performance - Cenovus shares have declined approximately 22.4% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3]. - The current Zacks Rank for Cenovus is 3 (Hold), indicating expected performance in line with the market in the near future [6]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $9.21 billion, and for the current fiscal year, it is $1.41 on revenues of $37.83 billion [7]. - The outlook for the industry, specifically the Oil and Gas - Integrated - Canadian sector, is currently in the top 24% of Zacks industries, suggesting a favorable environment for performance [8].

Lincoln National (LNC) came out with quarterly earnings of $1.60 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.90%. A quarter ago, it was expected that this insurance and retirement business would post earnings of $1.74 per share when it actually produced earnings of $1.91, delivering a surprise of 9.77%.Over the last fou ...

Millicom International Cellular SA (TIGO) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.27%. A quarter ago, it was expected that this company would post earnings of $0.78 per share when it actually produced earnings of $0.20, delivering a surprise of -74.36%.Over the last four qu ...

Jackson Financial (JXN) came out with quarterly earnings of $5.10 per share, beating the Zacks Consensus Estimate of $4.93 per share. This compares to earnings of $4.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.45%. A quarter ago, it was expected that this financial services company would post earnings of $4.72 per share when it actually produced earnings of $4.65, delivering a surprise of -1.48%.Over the last four qua ...

AerSale Corporation (ASLE) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of $0.13. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -138.46%. A quarter ago, it was expected that this company would post earnings of $0.07 per share when it actually produced earnings of $0.09, delivering a surprise of 28.57%. Over the last four quarters, the company has s ...

Core Viewpoint - GoodRx Holdings, Inc. reported quarterly earnings of $0.09 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.08 per share a year ago [1] - The company posted revenues of $202.97 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 0.19% and up from $197.88 million year-over-year [2] Financial Performance - GoodRx's earnings have not surpassed consensus EPS estimates over the last four quarters [1] - The company has topped consensus revenue estimates only once in the past four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $205.65 million, and for the current fiscal year, it is $0.40 on revenues of $824.14 million [7] Market Performance - GoodRx shares have declined approximately 8.4% since the beginning of the year, compared to a 4.7% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Industry Outlook - The Medical Services industry, to which GoodRx belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact GoodRx's stock performance [5]